Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614000361606
Ethics application status
Approved
Date submitted
28/03/2014
Date registered
7/04/2014
Date last updated
16/11/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
High concentration oxygen in Chronic Obstructive Pulmonary Disease (COPD)
Scientific title
Response of Patients with COPD to Hyperoxia and Normoxia, as Measured by Carbon Dioxide Levels.
Secondary ID [1] 284321 0
Nil.
Universal Trial Number (UTN)
U1111-1150-9928
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
COPD 291469 0
Condition category
Condition code
Respiratory 291836 291836 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
50% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive airway pressure. Followed by a 30 minute washout period.
Intervention code [1] 289039 0
Treatment: Other
Comparator / control treatment
21% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive airway pressure. Followed by a 30 minute washout period.
Control group
Placebo

Outcomes
Primary outcome [1] 291754 0
Transcutaneous carbon dioxide level, as measured by a TOSCA monitor.
Timepoint [1] 291754 0
30 minutes.
Secondary outcome [1] 307416 0
Transcutaneous carbon dioxide level, as measured by a TOSCA monitor.
Timepoint [1] 307416 0
10 and 20 minutes.
Secondary outcome [2] 307417 0
Respiratory rate, measured from capnography equipment.
Timepoint [2] 307417 0
10, 20 and 30 minutes.
Secondary outcome [3] 307418 0
Minute ventilation, calculated using data from a flow sensor attached to the expiratory port of the participant's mask.
Timepoint [3] 307418 0
10, 20 and 30 minutes.
Secondary outcome [4] 307419 0
Volume of dead space to tidal volume, calculated using data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [4] 307419 0
10, 20 and 30 minutes.
Secondary outcome [5] 307420 0
Change in transcutaneous carbon dioxide greater than or equal to 4mmHg, as measured by the TOSCA monitor.
Timepoint [5] 307420 0
30 minutes.
Secondary outcome [6] 307421 0
Change in transcutaneous carbon dioxide greater than or equal to 10mmHg, as measured by the TOSCA monitor.
Timepoint [6] 307421 0
30 minutes.
Secondary outcome [7] 307422 0
Effect of baseline transcutaneous carbon dioxide (measured via TOSCA) and FEV1 (measured via spirometry) on outcomes.
Timepoint [7] 307422 0
Baseline.
Secondary outcome [8] 307423 0
Tidal volume, calculated using data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [8] 307423 0
10, 20 and 30 minutes.
Secondary outcome [9] 307424 0
Volume of dead space, calculated using data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [9] 307424 0
10, 20 and 30 minutes.
Secondary outcome [10] 307425 0
Alveolar volume, calculated using data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [10] 307425 0
10, 20 and 30 minutes.
Secondary outcome [11] 307426 0
Alveolar minute ventilation, calculated using data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [11] 307426 0
10, 20 and 30 minutes.
Secondary outcome [12] 307427 0
Oxygen saturations, as recorded on the TOSCA via continuous electronic recording data download.
Timepoint [12] 307427 0
Continuously over the timecourse of the intervention and washout period.
Secondary outcome [13] 307428 0
Heart rate, measured from the TOSCA.
Timepoint [13] 307428 0
10, 20 and 30 minutes.
Secondary outcome [14] 307429 0
Evaluation of outcomes above in comparason to results from a study of the same design in patients with bronchiectasis (ACTRN12612000356864).
Timepoint [14] 307429 0
Time points as above.

Eligibility
Key inclusion criteria
COPD, as diagnosed by a doctor.
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Baseline transcutaneous carbon dioxide of greater than or equal to 60mmHg
2. FEV1:FVC ratio >0.7
3. Age under 16 years
4. A diagnosis of bronchiectasis
5. Morbid obesity (with a body mass index of greater than or equal to 40)
6. Inability to match FEV1 percentage predicted to a participant that took part in the bronchiectasis oxygen study*
7. Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.

*This study is designed to allow for comparison of results to a study of similar design in patients with bronchiectasis (ACTRN12612000356864). Participants will therefore be matched by FEV1 to the participants in the bronchiectasis study (the COPD participant must have an FEV1 percentage predicted within an absolute value of 5% of the FEV1 percentage predicted for the bronchiectasis patient (values inclusive)).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Following explanation of the trial and consent, participants will be assessed for eligibility. If eligible, participants will be randomised to the order of interventions (21% oxygen and 50% oxygen). This order will be available to an investigator who is not administering treatment, assessing outcomes or analysing data. Their role is to make available the gas bottles and bags (containing either 21% oxygen or 50% oxygen) in the randomised order. The labels on the bottles will be covered to maintain blinding of other investigators and the participant.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
By computer.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Crossover
Other design features
Outcomes will be adjusted for baseline in the data analysis.
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
14/04/2014
Actual
10/06/2014
Date of last participant enrolment
Anticipated
Actual
21/01/2015
Date of last data collection
Anticipated
Actual
Sample size
Target
24
Accrual to date
Final
24
Recruitment outside Australia
Country [1] 5919 0
New Zealand
State/province [1] 5919 0

Funding & Sponsors
Funding source category [1] 288958 0
Government body
Name [1] 288958 0
Health Research Council of New Zealand
Country [1] 288958 0
New Zealand
Funding source category [2] 288959 0
Charities/Societies/Foundations
Name [2] 288959 0
Medical Research Institute of New Zealand
Country [2] 288959 0
New Zealand
Primary sponsor type
Charities/Societies/Foundations
Name
Medical Research Institute of New Zealand
Address
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country
New Zealand
Secondary sponsor category [1] 287637 0
None
Name [1] 287637 0
Nil.
Address [1] 287637 0
Country [1] 287637 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 290769 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 290769 0
Ethics committee country [1] 290769 0
New Zealand
Date submitted for ethics approval [1] 290769 0
Approval date [1] 290769 0
24/12/2013
Ethics approval number [1] 290769 0
13/STH/200

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 47202 0
Dr Janine Pilcher
Address 47202 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington, 6021
Country 47202 0
New Zealand
Phone 47202 0
+64 4 8050241
Fax 47202 0
Email 47202 0
[email protected]
Contact person for public queries
Name 47203 0
Janine Pilcher
Address 47203 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington, 6021
Country 47203 0
New Zealand
Phone 47203 0
+64 4 8050241
Fax 47203 0
Email 47203 0
[email protected]
Contact person for scientific queries
Name 47204 0
Janine Pilcher
Address 47204 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington, 6021
Country 47204 0
New Zealand
Phone 47204 0
+64 4 8050241
Fax 47204 0
Email 47204 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
ThesisNo https://researcharchive.vuw.ac.nz/xmlui/handle/100... [More Details]

Documents added automatically
No additional documents have been identified.